Association of IFNAR2 rs2236757 and OAS3 rs10735079 Polymorphisms with Susceptibility to COVID-19 Infection and Severity in Palestine

Table 6

Association of IFNAR2 rs2236757 and OAS3 rs10735079 polymorphisms with COVID-19 signs and symptoms in the community patients and ICU patients, separately.

				Yes	No	OR (95% CI)	value
Community patients	rs2236757 (IFNAR2)	Loss of taste/smell	Codominant
			GG	18	17	ref	0.019
			GA	27	7	3.57 (1.19–10.72)
			AA	0	0	NA
		Muscle aches	Codominant
			GG	17	18	ref	0.0254
			GA	25	9	3.65 (1.12–11.86)
			AA	0	0	NA
		Dyspnea	Codominant
			GG	8	27	ref	0.006
			GA	16	18	4.84 (1.45–16.13)
			AA	0	0	NA
	rs10735079 (OAS3)	Sore throat	Codominant
			GG	9	10	ref	0.042
			GA	15	15	1.13 (0.33–3.89)
			AA	3	17	0.21 (0.04–1.01)
			Dominant
			GG	9	10	Ref	0.408
			GA + AA	18	32	0.62 (0.20–1.93)
			Recessive^†
			GG + GA	24	25	ref	0.012
			AA	3	17	0.19 (0.05–0.79)
			Over dominant
			GG + AA	12	27	ref	0.143
			GA	15	15	2.21 (0.76–6.45)
			Log additive
				27	42	0.50 (0.24–1.02)	0.051
ICU patients	rs10735079 (OAS3)	Muscle aches	Codominant
			GG	11	2	ref	0.042
			GA	6	2	0.26 (0.01–5.08)
			AA	4	6	0.05 (0.00–1.06)
			Dominant
			GG	11	2	ref	0.046
			GA + AA	10	8	0.11 (0.01–1.41)
			Recessive
			GG + GA	17	4	ref	0.023
			AA	4	6	0.11 (0.01–0.91)
			Over dominant
			GG + AA	15	8	ref	0.698
			GA	6	2	1.48 (0.20–10.84)
			Log additive^†
				21	10	0.22 (0.05–0.99)	0.014

^†Best model to explain the association according to the Akaike information criterion. The odds ratios and the values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction, a value <0.025 was considered significant. OR, odds ratio; ref, reference; NA, not applicable. values below the significance threshold are highlighted in bold.